Administration of a selective il-6-trans-signalling inhibitor

A method for the treatment of an inflammatory disease or an IL-6-mediated condition in a human, said method comprising administering to a human in need thereof 0.5 mg to 5 g of a polypeptide dimer, wherein the polypeptide dimer comprises two monomers, each monomer having at least 90% sequence identity to SEQ ID NO:

• 1, wherein the monomers comprise the gp130 D6 domain corresponding to the amino acids at positions 585-595 of SEQ ID NO:1, an Fc domain hinge region comprising the amino acids at positions 609-612 of SEQ ID NO:1, and the monomers do not comprise a linker between the gp130 D6 domain and the Fc domain hinge region.

A method for treating an IL-6-mediated condition in a human comprising administering to a human in need thereof a polypeptide dimer comprising two monomers, each monomer having at least 90% sequence identity to SEQ ID NO:

• 1, wherein the monomers comprise the gp130 D6 domain corresponding to the amino acids at positions 585-595 of SEQ ID NO:1, an Fc domain hinge region comprising the amino acids at positions 609-612 of SEQ ID NO:1, and the monomers do not comprise a linker between the gp130 D6 domain and the Fc domain hinge region, such that the IL-6-mediated condition is treated without significantly lowering neutrophil counts, platelet counts and/or levels of C-reactive protein or without lowering neutrophil counts, platelet counts and/or levels of C-reactive protein below a normal range in healthy subjects or patients suffering from an IL-6-mediated condition.